|
ISPOR BOARD OF DIRECTORS TAKE ACTION IN 2005
ISPOR 2004-2005 Board of Directors (Jan 1-June 30, 2005):
President - Lieven Annemans, PhD, HEDM, Ghent University,
HEDM and IMS Health; Past- President - Sean Sullivan, PhD,
University of Washington; President-elect - Peter Neumann, ScD,
Tufts University School of Medicine; Directors - Randel E.
Richner, BSN, MPH, Boston Scientific Corporation, and Marcus D.
Wilson, PharmD, Health Core, Inc.; Laurie Burke, MPH, RPh, FDA,
Jens Grueger, PhD, Novartis, Isao Kamae MD, DrPH, Kobe
University; Treasurer- Lorne Basskin PharmD, Healthsouth Sunrise
Rehabilitation Hospital; Executive Director - Marilyn Dix Smith,
RPh, PhD, ISPOR. ISPOR. ISPOR 2005-2006 Board of Directors
(July 1-Dec 31, 2005): Peter J. Neumann, ScD, Tufts
University School of Medicine; Past- President - Lieven Annemans,
PhD, HEDM, Ghent University, HEDM and IMS Health;
President-elect - Michael Drummond, PhD, University of York;
Directors - Joyce Cramer, Yale University School of Medicine;
Scott Ramsey, MD, PhD, Fred Hutchinson Cancer Research Center;
Laurie Burke, MPH, RPh, FDA; Jens Grueger, PhD, Novartis
Pharmaceuticals AG; Isao Kamae, MD, DrPH, Kobe University;
Treasurer- Lorne Basskin, PharmD, Healthsouth Sunrise
Rehabilitation Hospital; Executive Director - Marilyn Dix Smith,
RPh, PhD, ISPOR. The ISPOR 2004-2005 and 2005-2006 Boards of
Directors had yet another busy year in 2005. The Boards met
six times (4 teleconferences and 2 face-to-face meetings). The
Board approved the following:
ISPOR Policy & Procedures Actions:
- ISPOR Special Interest Groups are evaluated every 2 years
based on criteria developed by the Board.
Financial Actions:
- ISPOR offers to waive the ISPOR membership fee for
individuals from economically developing countries up to 1% of
our membership, upon request and for those who meet the criteria
(documentation of citizenship and financial need determined by
ISPOR staff).
- 2005 budget approved.
- Audit Report containing no recommended changes approved.
Award Actions:
- ISPOR Service Awardees approved for ISPOR Board of
Directors, Avedis Donebedian Lifetime Achievement Awardee,
Bernie O'Brien New Investigator Awardee, Research Excellence
Awardees, Distinguished Service Awardees (Student Chapter
Presidents, Committee/Task Force/Special Interest Group Chairs
as well as past Committee/Task Force/Special Interest Group
Chairs, who produced a tangible product such as a paper. See
the ISPOR website for awardees.
ISPOR Publication Actions:
- John Hornberger MD, MS was approved as Value in Health
coeditor.
- Michelle J. Naughton PhD, MPH as new Value in Health
co-editor for patient-reported outcomes papers and Adrian Levy
MSc, PhD, as new member of the Editorial Advisory Board were
approved.
Student Chapter Actions:
- The ISPOR Student Chapter at University of the Sciences in
Philadelphia, Philadelphia PA, USA; the ISPOR Student Chapter at Pompeu i Fabra University, Barcelona, Spain; the ISPOR Student
Chapter - Harvard School of Public Health; and the Student
Chapter at University of Arkansas Medical Sciences were
approved.
Local Chapter Actions:
- The ISPOR Taiwan Chapter and the ISPOR Czech Chapter
were approved.
Meetting Actions:
- • The ISPOR Asia Consortium Executive Committee
recommendation that the next Asia-Pacific Conference be held
in Shanghai, China March 2006 was approved.
- • The Board agreed that the format and programming for
future International Meetings should be reevaluated.
Committee / Task Force / Council / Consortium Actions:
- For the ISPOR Vision 2010 Implementation Task Force, the
Board supports the addition to the ISPOR key vision areas,
“fostering outcomes research for medical devices, diagnostics,
and biotechnology”. However, this as a key area should be
re-evaluated in 3 years (when fully implemented), since this
activity should be an integral part of ISPOR. The Board
recommended that the Task Force develop a plan to assess the
need to change the ISPOR name. The Board recommended that the
ISPOR Education Committee review and comment on the ISPOR
Vision 2010 Implementation Task Force Framework Action on the
key vision area, 'Promoting Education'. The Board recommended
that the Task Force to continue with the other key vision
areas (International Growth, Fostering Research Excellence,
Reach out to Decision Makers, Foster Outcomes Research for
Medical Devices, Diagnostics & Biotechnology Products) but to
limit the proposed framework to proposed new action, proposed
resources needed, proposed structural changes, classification
of actions, and identification of key actors.
- ISPOR Institutional Council's recommendation was approved
that ISPOR take an active role in the development of ePRO good
research practices addressing specific issues recommended by the
Council and that the ISPOR Patient Reported Outcomes Special
Interest Group consider this task under its leadership. It was
suggested that the PRO SIG carefully consider a balanced, broad
representation for the ePRO Working Group.
Health Science Actions:
- The Budget Impact Analysis Task Force whose mission is to
develop a coherent set of methodological guidelines for those
developing or reviewing budget impact analyses was approved.
- The Task Force on Good Research Practices in Costing of
Health Technologies was approved to develop standards for drug
costs in pharmacoeconomic studies, review current practice for
estimating drug costs in pharmacoeconomic studies undertaken
in major markets, review conceptual and methodologic
literature on drug price, patent protection and social
opportunity costs, from a global perspective. This Task Force
is under the leadership of the Health Science Policy Council.
- The Task Force on Good Research Practices on
Transferability of Economic Data in Health Technology
Assessment was approved to define key variable economic data,
define guidelines for acceptance data from outside a country
taking into consideration existing national guidelines. This
Task Force is under the leadership of the Health Science
Policy Council.
- The Evidence-based Health Care Decision-making Task Force
was approved to develop a plan for the following:
- recruit a senior advisory panel to define the problem and
work plan
- review, describe, and report on existing evidence-based
medicine (EBM) applications
- review and report on EBM methods literature • develop
consensus for definitions of words and phrases in EBM and
report
- review and report on methods for combining disparate sets
of evidence.
- The Quality Assessment for Cost-effective Health Care
Research and Global Policy Task Force was approved to explore
(through surveys, white papers, and sessions at ISPOR
meetings) the following:
— development of periodic reports on the state and quality of
costeffectiveness analysis and outcomes science and practice,
— development of additional recognition of good research,
— development of a report card on quality of outcomes research (papers,
abstracts), journal guidelines, government guidelines, and
— development of a repository of “reference case” CEA models.
This Task Force is under the leadership of the Health Science
Policy Council.
|
